Gunilla Karlsson Hedestam and Ganesh Phad publish in the Journal of Experimental Medicine

Thanks to the isolation of highly potent, broadly neutralizing antibodies (bNAbs) against HIV-1, immunotherapy has emerged as a potentially viable approach to treat chronic infection. This paper in JEM shows that frequently arising non-broadly neutralizing antibodies that normally fail to control HIV-1 infection on their own can synergize with passively administered bNAbs by preventing the emergence of bNAb viral escape variants. These results suggest that immunotherapy may have significant value as an alternative approach to conventional drug therapy.

Read the paper in JEM: Enhanced HIV-1 immunotherapy by naturally arising antibodies targeting resistant variants